Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

IMWG consensus on risk stratification in multiple myeloma.

Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group.

Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26. Review.

PMID:
23974982
2.
3.

Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement.

Durie BG.

Mayo Clin Proc. 2007 Apr;82(4):516-7; author reply 517-8. No abstract available.

PMID:
17418085
4.

Genomics in multiple myeloma: biology and clinical implications.

Chng WJ, Fonseca R.

Pharmacogenomics. 2005 Sep;6(6):563-73.

PMID:
16142997
5.

[Updated criteria for diagnosis and risk stratification in patients with multiple myeloma].

Djurdjević P, Andjelković N, Bila J.

Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:95-102. Serbian.

6.

IMWG consensus on maintenance therapy in multiple myeloma.

Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M; International Myeloma Working Group.

Blood. 2012 Mar 29;119(13):3003-15. doi: 10.1182/blood-2011-11-374249. Epub 2012 Jan 23. Review.

7.

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.

Barbee MS, Nooka A, Kaufman JL, Kim S, Chen Z, Heffner LT Jr, Lonial S, Harvey RD.

Cancer. 2015 Mar 15;121(6):853-62. doi: 10.1002/cncr.29136. Epub 2014 Nov 6.

8.

Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma.

Claudio JO, Stewart AK.

Am J Pharmacogenomics. 2005;5(1):35-43. Review.

PMID:
15727487
9.

Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.

Rajkumar SV, Buadi F.

Best Pract Res Clin Haematol. 2007 Dec;20(4):665-80. Review.

PMID:
18070712
10.

A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.

Iriuchishima H, Saitoh T, Handa H, Isoda A, Matsumoto M, Sawamura M, Iwasaki A, Ushie C, Hattori H, Sasaki Y, Mitsui T, Yokohama A, Tsukamoto N, Murakami H, Nojima Y.

Eur J Haematol. 2015 Feb;94(2):145-51. doi: 10.1111/ejh.12407. Epub 2014 Jul 24.

PMID:
24981274
11.

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.

Peñalver FJ, Delgado J, Loscertales J, Sastre JL, Peña A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Pérez Ceballos E, Debén G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ, Mateos MV.

Eur J Haematol. 2016 May;96(5):532-40. doi: 10.1111/ejh.12633. Epub 2015 Aug 9.

PMID:
26179864
12.

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.

Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV; International Myeloma Working Group.

Blood. 2009 Aug 27;114(9):1729-35. doi: 10.1182/blood-2009-04-205013. Epub 2009 Jun 26.

13.

Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma.

Yeung J, Chang H.

J Clin Pathol. 2008 Jul;61(7):832-6. Epub 2007 Dec 12. Review.

PMID:
18077770
14.

Development of early treatment strategies for high-risk myeloma precursor disease in the future.

Landgren O, Rajkumar SV.

Semin Hematol. 2011 Jan;48(1):66-72. doi: 10.1053/j.seminhematol.2010.11.009. Review.

PMID:
21232660
15.

International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.

Scudla V, Zemanova M, Minarik J, Bacovsky J, Ordeltova M, Indrak K, Budikova M, Dusek L, Farbiakova V.

Neoplasma. 2006;53(4):277-84.

PMID:
16830053
16.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF.

Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. Review.

17.

[Classification, staging and prognostic indices for multiple myeloma].

Hotta T.

Nihon Rinsho. 2007 Dec;65(12):2161-6. Review. Japanese.

PMID:
18069256
18.

Optimising patient outcomes in myeloma.

Harousseau JL.

Cancer Treat Rev. 2010 May;36 Suppl 2:S33-5. doi: 10.1016/S0305-7372(10)70010-4. Review.

PMID:
20472187
19.

Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma.

Amodio N, Di Martino MT, Neri A, Tagliaferri P, Tassone P.

Expert Opin Biol Ther. 2013 Jun;13 Suppl 1:S125-37. doi: 10.1517/14712598.2013.796356. Epub 2013 May 22. Review.

PMID:
23692413
20.

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.

Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Müller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H.

Haematologica. 2010 Jul;95(7):1150-7. doi: 10.3324/haematol.2009.016436. Epub 2010 Mar 10.

Supplemental Content

Support Center